Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Skovagervej 2, 8240 Risskov, Denmark.
Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Skovagervej 2, 8240 Risskov, Denmark.
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:27-38. doi: 10.1016/j.pnpbp.2016.05.007. Epub 2016 Jun 2.
A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist, may alleviate depressive symptoms within hours of administration in treatment resistant depressed patients, and the antidepressant effect may last for several weeks. These unique therapeutic properties have prompted researchers to explore the mechanisms mediating the antidepressant effects of ketamine, but despite many efforts, no consensus on its antidepressant mechanism of action has been reached. Recent preclinical reports have associated the neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) with the antidepressant-like action of ketamine. Here, we review the current evidence for a serotonergic role in ketamine's antidepressant effects. The pharmacological profile of ketamine may include equipotent activity on several non-NMDA targets, and the current hypotheses for the mechanisms responsible for ketamine's antidepressant activity do not appear to preclude the possibility that non-glutamate neurotransmitters are involved in the antidepressant effects. At multiple levels, the serotonergic and glutamatergic systems interact, and such crosstalk could support the notion that changes in serotonergic neurotransmission may impact ketamine's antidepressant potential. In line with these prospects, ketamine may increase 5-HT levels in the prefrontal cortex of rats, plausibly via hippocampal NMDA receptor inhibition and activation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. In addition, a number of preclinical studies suggest that the antidepressant-like effects of ketamine may depend on endogenous activation of 5-HT receptors. Recent imaging and behavioral data predominantly support a role for 5-HT1A or 5-HT1B receptors, but the full range of 5-HT receptors has currently not been systematically investigated in this context. Furthermore, the nature of any 5-HT dependent mechanism in ketamine's antidepressant effect is currently not understood, and therefore, more studies are warranted to confirm this hypothesis and explore the specific pathways that might implicate 5-HT.
单次静脉输注氯胺酮,作为一种 N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,可能在数小时内缓解治疗抵抗性抑郁患者的抑郁症状,并且抗抑郁作用可能持续数周。这些独特的治疗特性促使研究人员探索氯胺酮抗抑郁作用的机制,但尽管进行了许多努力,仍未就其抗抑郁作用机制达成共识。最近的临床前报告将神经递质 5-羟色胺(5-HT)与氯胺酮的抗抑郁作用联系起来。在这里,我们综述了目前关于氯胺酮的抗抑郁作用与 5-羟色胺有关的证据。氯胺酮的药理学特征可能包括对几个非 NMDA 靶点的等效活性,并且目前关于导致氯胺酮抗抑郁活性的机制的假设似乎不排除非谷氨酸能神经递质参与抗抑郁作用的可能性。在多个水平上,5-羟色胺能和谷氨酸能系统相互作用,这种串扰可以支持这样一种观点,即 5-羟色胺能神经递质的变化可能会影响氯胺酮的抗抑郁潜力。根据这些前景,氯胺酮可能会增加大鼠前额叶皮层的 5-HT 水平,这可能是通过海马 NMDA 受体抑制和激活 α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体来实现的。此外,许多临床前研究表明,氯胺酮的抗抑郁样作用可能取决于内源性激活 5-HT 受体。最近的成像和行为数据主要支持 5-HT1A 或 5-HT1B 受体的作用,但在这种情况下,目前尚未系统地研究 5-HT 受体的全部范围。此外,氯胺酮抗抑郁作用中任何 5-HT 依赖性机制的性质目前尚不清楚,因此,需要更多的研究来证实这一假设,并探索可能涉及 5-HT 的具体途径。